Pfizer’s Glucotrol XL Generic Not Cutting Into Andrx’ Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's introduction of its own Glucotrol XL generic has not impacted Andrx' market share for glipizide extended-release, the generic company said during an Aug. 10 earnings call
You may also be interested in...
Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity
FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.